SIRPant-M

Phase 1Biologic

SSIRPant Immunotherapeutics, Inc.

SIRPant-M is one of 40 biologic programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaRecruiting

LymphomaPhase 1

Recruiting

Competition

Competitive Landscape

384 competitors in Lymphoma

#DrugCompanyPhaseTrials

Zofran

Novartis

Preclinical

2 2

Norvir

AbbVie

Preclinical

1 3

Cabenuva

GSK

Preclinical

1 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—8

Decadron

QQuince Therapeutics S.p.A.

Systemic Therapy

1 10

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma1 trial

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting·SSIRPant Immunotherapeutics, Inc.·Phase 1·NCT05967416·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SIRPant-M. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SIRPant-M compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SIRPant-M. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SIRPant Immunotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSIRPant Immunotherapeutics, Inc.

SIRPant-M

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News